The strategy of single therapy with MEK inhibitors may activate another parallel signaling pathway, that causes resistance to MEK inhibitors, and previous studies have shown that monotherapy with MEK inhibitors has lower efficacy and greater toxicity for NSCLC patients than chemotherapy alone [61]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.